Developer docs
API playgroundTry for free, no card

Search company profiles

Diatech Pharmacogenetics

Full company profile

uuid00094zo

Namestring
Diatech Pharmacogenetics
Legal namestring
Diatech Pharmacogenetics S.r.l.
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Diatech Pharmacogenetics is an Italian molecular diagnostics company headquartered in Jesi, Italy, specializing in precision medicine for oncology and pharmacogenetics. Founded in 1996, the company develops and distributes CE-IVD marked in vitro diagnostic kits built on Agena Bioscience's MassARRAY technology platform, with its flagship Myriapod® system enabling highly multiplexed analysis of SNPs and actionable mutations in a single assay and delivering results from patient DNA to therapy selection in under one day. The product portfolio spans solid tumor diagnostics (KRAS, NRAS, BRAF, EGFR, ALK for colon, lung, and melanoma), blood cancer testing (NPM1 for AML, CML monitoring), and pharmacogenetics panels (DPYD, UGT1A1, CYP2D6, TPMT/NUDT15) to guide chemotherapy dosing, supplemented by the Labcycler PCR thermal cycler instrument and an NGS module. The company also operates four wholly-owned subsidiaries covering distribution, gene synthesis, healthcare IT software, and small-molecule discovery.

Diatech serves hospital and independent clinical laboratories, oncology and hematology departments, and pharmaceutical partners across Italy, Germany, the UK, France, and the MEA region. Its go-to-market combines direct B2B enterprise sales through a registered customer portal with channel partnerships (Merck Serono for MEA distribution, Agena Bioscience for European MassARRAY Dx PLUS rollout) and technology integrations with Illumina, Revvity, and ArcherDX. Revenue mechanics are driven by one-time kit and instrument sales, licensing/royalty arrangements with technology partners, and quote-based pricing negotiated with institutional buyers. The company is privately held following PE transactions by Alto Partners (40% stake, 2021) and TA Associates (minority stake, 2023) and maintains EN ISO 9001, EN ISO 13485, and IVDR certifications.

Short descriptiontext

Diatech Pharmacogenetics is an Italian molecular diagnostics company that develops CE-IVD marked kits and the Myriapod® system for precision oncology and pharmacogenetics testing, serving clinical laboratories, hospitals, and pharmaceutical partners across Europe and the MEA region.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersJesi, Italy
HQ citystring
Jesi
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics kits, pharmacogenetics testing, precision oncology diagnostics, CE-IVD diagnostic assays, PCR thermal cyclers
Industry3 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Laboratories621511
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Molecular Diagnostic Kits and Tests
TypeOne Time License
Description

Sale of CE-IVD marked diagnostic kits including Myriapod product line for solid tumor, blood cancer, and pharmacogenetics testing. The kits analyze tens of mutations in a single session and provide results from patient's DNA to personalized therapy choice in less than one day.

diatechpharmacogenetics.com
2Labcycler Instruments
TypeHardware Sales
Description

Sale of Labcycler PCR thermal cycler instruments designed for research, diagnostic and biotechnology laboratories. The instrument is a compact and highly reliable PCR thermal cycler with advanced thermal control and interchangeable block system.

diatechpharmacogenetics.com
3RAS Biomarker Testing
TypeOne Time License
Description

Diagnostic testing services for RAS biomarkers in colorectal cancer, particularly in partnership with Merck for MEA region expansion.

diatechpharmacogenetics.com
4OEM/Embedded Technology Licensing
TypeLicensing Royalties
Description

Technology partnerships with Illumina, Revvity, ArcherDX, and Agena Bioscience involving integration and distribution of diagnostic solutions.

diatechpharmacogenetics.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1B2B enterprise pricing through reserved customer area
ModelOtherBilling cadencePay-as-you-go
Notes

Products are available through a registered customer portal for healthcare professionals. Pricing appears to be quote-based / negotiated for institutional buyers.

diatechpharmacogenetics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Myriapod
Description

CE-IVD in vitro diagnostic line that permits identification of SNPs which could give adverse response to drugs used for specific neoplastic pathology treatment. Enables analysis of tens of mutations in a single session.

diatechpharmacogenetics.com
Core offering1 text field

Diatech Pharmacogenetics develops, manufactures, and distributes CE-IVD marked molecular diagnostic kits and instruments for precision oncology and pharmacogenetics. Its flagship Myriapod® system enables identification of SNPs and actionable mutations (KRAS, NRAS, BRAF, EGFR, ALK) in solid tumors, blood cancers, and pharmacogenetic applications, delivering personalized therapy recommendations in less than one day. The company also manufactures the Labcycler PCR thermal cycler instrument for research and diagnostic laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Results from patient DNA to personalized therapy choice in less than one day
+4 more records
Product overview1 text field

Diatech Pharmacogenetics is an Italian molecular diagnostics company providing pharmacogenetic testing solutions dedicated to personalized and predictive medicine, with priority focus on anti-cancer treatments. The company's portfolio centers on the Myriapod® system, a CE-IVD marked in vitro diagnostic line that enables identification of genetic biomarkers affecting drug response with results in less than one day. The Myriapod ecosystem includes multiple product lines: Myriapod NGS for next-generation sequencing, Myriapod® Dx PLUS for multiplexed mutation analysis in solid tumors (KRAS, NRAS, BRAF, EGFR, ALK), Easy and Easy PGX for pharmacogenetics testing, Helix for NGS library preparation, Microsatelliti for microsatellite instability detection, Realquant for quantitative PCR, and Response for treatment response biomarkers. The company also distributes the Labcycler PCR thermal cycler instrument. Products support solid tumor testing, blood cancer diagnostics, and pharmacogenetics across oncology applications.

Product and service10 records
1Myriapod®
CategoryMolecular Diagnostic System
Description

CE-IVD marked in vitro diagnostic system enabling identification of SNPs that could give adverse response to drugs used for specific neoplastic pathology treatment. Analyzes tens of mutations in a single session, delivering results from patient DNA to personalized therapy choice in less than one day. Targeted at hospital and clinical laboratories performing molecular diagnostics.

2Myriapod® Dx PLUS
CategoryMolecular Diagnostic Assays
Description

CE-IVD marked assay system providing parallel analysis of frequently observed and actionable mutations in colon, lung, and melanoma tumors using MassARRAY technology. Tests for KRAS, NRAS, BRAF, EGFR, and ALK genes. Designed for oncology and clinical diagnostic laboratories.

3Myriapod NGS
CategoryNext-Generation Sequencing
Description

Next-generation sequencing module within the Myriapod ecosystem for advanced genomic analysis and molecular diagnostics in oncology applications.

4Easy PGX
CategoryPharmacogenetics Testing
Description

Pharmacogenetics testing product line for predicting drug response and adverse reactions based on genetic variants, focused on anti-cancer treatments including 5-FU/capecitabine (DPYD), irinotecan (UGT1A1), tamoxifen (CYP2D6), and thiopurine therapy (TPMT/NUDT15).

5Easy
CategoryMolecular Diagnostics
Description

Product line for molecular diagnostics testing within the Diatech Pharmacogenetics portfolio, covering core molecular diagnostic applications.

6Helix
CategoryNGS Library Preparation
Description

Product line within the Myriapod ecosystem for NGS library preparation and genomic analysis.

7Microsatelliti
CategoryCancer Diagnostics
Description

Product line for microsatellite instability testing in cancer diagnostics.

8Realquant
CategoryQuantitative PCR
Description

Product line for quantitative real-time PCR analysis in molecular diagnostics.

9Response
CategoryTreatment Response Biomarkers
Description

Product line focused on biomarkers for monitoring and predicting treatment response in oncology.

10Labcycler
CategoryLaboratory Instruments
Description

Compact and highly reliable PCR thermal cycler designed by German engineering and manufactured by Diatech Pharmacogenetics. Supports daily needs of research, diagnostic, and biotechnology laboratories with advanced thermal control, interchangeable block system, and intuitive touch screen interface.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-29
Description

Expanded collaboration to improve patient access to RAS biomarker testing for colorectal cancer in the Middle East and Africa regions. The partnership aims to advance healthcare solutions and enable timely, accurate genetic testing for metastatic colorectal cancer patients across the MEA region.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2015-10-27
Description

Strategic partnership for development and commercial launch of CE-IVD marked MassARRAY Dx PLUS assays for gene-specific mutation testing. Diatech built its CE-IVD marked Myriapod system and assays based on Agena Bioscience's MassARRAY technology.

Strategic tierStrategicTypeTechnology or Integration
Description

Global genomics and human health partnership. Illumina develops DNA sequencing and array-based life sciences technologies enabling research discovery and personalized health. Diatech integrates genomic solutions across oncology applications.

Strategic tierStrategicTypeTechnology or Integration
Description

Science-solutions partnership providing instruments, reagents, assays and software. Revvity offers global workflow capabilities from research to clinical applications in pharma, biotech, diagnostics, and healthcare.

5ArcherDX, Inc.
Strategic tierStrategicTypeTechnology or Integration
Description

Genomic analysis partnership advancing precision oncology through products and services leveraging proprietary Anchored Multiplex PCR (AMP) chemistry and informatics platform for advanced detection of gene fusions, variants, and biomarkers.

diatechpharmacogenetics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major molecular diagnostics and women's health company with IVD kits sold globally. Comparable as an established IVD kit manufacturer with regulatory expertise, though with broader product portfolio and stronger US footprint.

TypeBroad incumbent
Description

Global molecular diagnostics and sample-preparation leader with oncology and pharmacogenetics test menus. Comparable because both sell IVD molecular diagnostic kits to clinical labs and run parallel PCR- and NGS-based workflows, though Qiagen operates at much broader scale.

TypeBroad incumbent
Description

US-based oncology-focused clinical laboratory and IVD provider offering molecular and pharmacogenomic testing. Comparable because both serve oncologists and hematologists with molecular biomarker testing for therapy selection, though NeoGenomics operates primarily as a reference lab rather than a kit vendor.

TypeBroad incumbent
Description

Diagnostics and life-science reagents company with a molecular diagnostics portfolio including ExoDx and protein biomarker assays. Comparable as a B2B IVD kit vendor serving clinical labs, though with a broader reagents portfolio and US-centric distribution.

TypeDirect peer
Description

Molecular diagnostics and precision oncology company offering comprehensive tumor profiling. Comparable as a precision oncology diagnostics provider offering molecular profiling for therapy selection, though Caris operates primarily as a reference lab rather than selling kits.

TypeDirect peer
Description

Developer of molecular profiling technologies and assays for oncology applications. Direct peer because both target clinical labs with multiplexed gene-expression and mutation profiling assays for solid tumor and hematology applications.

TypeBroad incumbent
Description

Established molecular diagnostics company with oncology and pharmacogenetics test offerings. Comparable as a long-standing IVD molecular diagnostics player serving oncologists, though with a US-centric focus and broader hereditary cancer testing franchise.

TypeDirect peer
Description

Developer of the MassARRAY technology on which Diatech's Myriapod system is built. Direct peer because both commercialize MassARRAY-based CE-IVD diagnostic assays for oncology mutation testing, including the jointly launched MassARRAY Dx PLUS line.

TypeBroad incumbent
Description

Subsidiary of Danaher operating the GeneXpert molecular diagnostics platform. Comparable as a global molecular IVD vendor with oncology and infectious disease menus sold to hospital labs, though at much larger scale and with broader regulatory clearances.

TypeDirect peer
Description

Molecular diagnostics company focused on oncology genomic testing. Comparable as a developer of molecular IVD tests for cancer diagnosis and treatment selection, with similar target customer base of hospital pathology labs and oncologists.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diatech Pharmacogenetics

Molecular Diagnosticsdiatechpharmacogenetics.com

Diatech Pharmacogenetics is an Italian molecular diagnostics company that develops CE-IVD marked kits and the Myriapod® system for precision oncology and pharmacogenetics testing, serving clinical laboratories, hospitals, and pharmaceutical partners across Europe and the MEA region.

What Diatech Pharmacogenetics does

Diatech Pharmacogenetics is an Italian molecular diagnostics company headquartered in Jesi, Italy, specializing in precision medicine for oncology and pharmacogenetics. Founded in 1996, the company develops and distributes CE-IVD marked in vitro diagnostic kits built on Agena Bioscience's MassARRAY technology platform, with its flagship Myriapod® system enabling highly multiplexed analysis of SNPs and actionable mutations in a single assay and delivering results from patient DNA to therapy selection in under one day. The product portfolio spans solid tumor diagnostics (KRAS, NRAS, BRAF, EGFR, ALK for colon, lung, and melanoma), blood cancer testing (NPM1 for AML, CML monitoring), and pharmacogenetics panels (DPYD, UGT1A1, CYP2D6, TPMT/NUDT15) to guide chemotherapy dosing, supplemented by the Labcycler PCR thermal cycler instrument and an NGS module. The company also operates four wholly-owned subsidiaries covering distribution, gene synthesis, healthcare IT software, and small-molecule discovery.

Diatech serves hospital and independent clinical laboratories, oncology and hematology departments, and pharmaceutical partners across Italy, Germany, the UK, France, and the MEA region. Its go-to-market combines direct B2B enterprise sales through a registered customer portal with channel partnerships (Merck Serono for MEA distribution, Agena Bioscience for European MassARRAY Dx PLUS rollout) and technology integrations with Illumina, Revvity, and ArcherDX. Revenue mechanics are driven by one-time kit and instrument sales, licensing/royalty arrangements with technology partners, and quote-based pricing negotiated with institutional buyers. The company is privately held following PE transactions by Alto Partners (40% stake, 2021) and TA Associates (minority stake, 2023) and maintains EN ISO 9001, EN ISO 13485, and IVDR certifications.

Diatech Pharmacogenetics firmographics

Firmographics
Name
Diatech Pharmacogenetics
Legal name
Diatech Pharmacogenetics S.r.l.
Website
https://diatechpharmacogenetics.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
51–100 employees
Short description
Diatech Pharmacogenetics is an Italian molecular diagnostics company that develops CE-IVD marked kits and the Myriapod® system for precision oncology and pharmacogenetics testing, serving clinical laboratories, hospitals, and pharmaceutical partners across Europe and the MEA region.
Ownership category
akta.pro rank

Diatech Pharmacogenetics industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Molecular diagnostics kits
  • Pharmacogenetics testing
  • Precision oncology diagnostics
  • CE-IVD diagnostic assays
  • PCR thermal cyclers

Where Diatech Pharmacogenetics is headquartered

Location

Headquarters

HQ city
Jesi
HQ country
Italy
HQ region
Europe

Offices1 record

Markets served

Diatech Pharmacogenetics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Molecular Diagnostic Kits and Tests: Sale of CE-IVD marked diagnostic kits including Myriapod product line for solid tumor, blood cancer, and pharmacogenetics testing. The kits analyze tens of mutations in a single session and provide results from patient's DNA to personalized therapy choice in less than one day.
  2. Labcycler Instruments: Sale of Labcycler PCR thermal cycler instruments designed for research, diagnostic and biotechnology laboratories. The instrument is a compact and highly reliable PCR thermal cycler with advanced thermal control and interchangeable block system.
  3. RAS Biomarker Testing: Diagnostic testing services for RAS biomarkers in colorectal cancer, particularly in partnership with Merck for MEA region expansion.
  4. OEM/Embedded Technology Licensing: Technology partnerships with Illumina, Revvity, ArcherDX, and Agena Bioscience involving integration and distribution of diagnostic solutions.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goB2B enterprise pricing through reserved customer area

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Diatech Pharmacogenetics product offering

Product offering

Core offering

Diatech Pharmacogenetics develops, manufactures, and distributes CE-IVD marked molecular diagnostic kits and instruments for precision oncology and pharmacogenetics. Its flagship Myriapod® system enables identification of SNPs and actionable mutations (KRAS, NRAS, BRAF, EGFR, ALK) in solid tumors, blood cancers, and pharmacogenetic applications, delivering personalized therapy recommendations in less than one day. The company also manufactures the Labcycler PCR thermal cycler instrument for research and diagnostic laboratories.

Product overview

Diatech Pharmacogenetics is an Italian molecular diagnostics company providing pharmacogenetic testing solutions dedicated to personalized and predictive medicine, with priority focus on anti-cancer treatments. The company's portfolio centers on the Myriapod® system, a CE-IVD marked in vitro diagnostic line that enables identification of genetic biomarkers affecting drug response with results in less than one day. The Myriapod ecosystem includes multiple product lines: Myriapod NGS for next-generation sequencing, Myriapod® Dx PLUS for multiplexed mutation analysis in solid tumors (KRAS, NRAS, BRAF, EGFR, ALK), Easy and Easy PGX for pharmacogenetics testing, Helix for NGS library preparation, Microsatelliti for microsatellite instability detection, Realquant for quantitative PCR, and Response for treatment response biomarkers. The company also distributes the Labcycler PCR thermal cycler instrument. Products support solid tumor testing, blood cancer diagnostics, and pharmacogenetics across oncology applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Myriapod: CE-IVD in vitro diagnostic line that permits identification of SNPs which could give adverse response to drugs used for specific neoplastic pathology treatment. Enables analysis of tens of mutations in a single session.

Products and services

  • Myriapod® CE-IVD marked in vitro diagnostic system enabling identification of SNPs that could give adverse response to drugs used for specific neoplastic pathology treatment. Analyzes tens of mutations in a single session, delivering results from patient DNA to personalized therapy choice in less than one day. Targeted at hospital and clinical laboratories performing molecular diagnostics.
  • Myriapod® Dx PLUS CE-IVD marked assay system providing parallel analysis of frequently observed and actionable mutations in colon, lung, and melanoma tumors using MassARRAY technology. Tests for KRAS, NRAS, BRAF, EGFR, and ALK genes. Designed for oncology and clinical diagnostic laboratories.
  • Myriapod NGS Next-generation sequencing module within the Myriapod ecosystem for advanced genomic analysis and molecular diagnostics in oncology applications.
  • Easy PGX Pharmacogenetics testing product line for predicting drug response and adverse reactions based on genetic variants, focused on anti-cancer treatments including 5-FU/capecitabine (DPYD), irinotecan (UGT1A1), tamoxifen (CYP2D6), and thiopurine therapy (TPMT/NUDT15).
  • Easy Product line for molecular diagnostics testing within the Diatech Pharmacogenetics portfolio, covering core molecular diagnostic applications.
  • Helix Product line within the Myriapod ecosystem for NGS library preparation and genomic analysis.
  • Microsatelliti Product line for microsatellite instability testing in cancer diagnostics.
  • Realquant Product line for quantitative real-time PCR analysis in molecular diagnostics.
  • Response Product line focused on biomarkers for monitoring and predicting treatment response in oncology.
  • Labcycler Compact and highly reliable PCR thermal cycler designed by German engineering and manufactured by Diatech Pharmacogenetics. Supports daily needs of research, diagnostic, and biotechnology laboratories with advanced thermal control, interchangeable block system, and intuitive touch screen interface.

Quantifiable outcome

  • Results from patient DNA to personalized therapy choice in less than one day
  • +4 more outcomes

Companies that use Diatech Pharmacogenetics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Diatech Pharmacogenetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Diatech Pharmacogenetics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and strategic.

  • Merck Serono Middle East Ltd. (affiliates of Merck KGaA)coreStrategic or Co-development Partner · 29 January 2025Expanded collaboration to improve patient access to RAS biomarker testing for colorectal cancer in the Middle East and Africa regions. The partnership aims to advance healthcare solutions and enable timely, accurate genetic testing for metastatic colorectal cancer patients across the MEA region.
  • Agena BiosciencecoreTechnology or Integration · 27 October 2015Strategic partnership for development and commercial launch of CE-IVD marked MassARRAY Dx PLUS assays for gene-specific mutation testing. Diatech built its CE-IVD marked Myriapod system and assays based on Agena Bioscience's MassARRAY technology.
  • Illumina, Inc.strategicTechnology or IntegrationGlobal genomics and human health partnership. Illumina develops DNA sequencing and array-based life sciences technologies enabling research discovery and personalized health. Diatech integrates genomic solutions across oncology applications.
  • Revvity, Inc.strategicTechnology or IntegrationScience-solutions partnership providing instruments, reagents, assays and software. Revvity offers global workflow capabilities from research to clinical applications in pharma, biotech, diagnostics, and healthcare.
  • ArcherDX, Inc.strategicTechnology or IntegrationGenomic analysis partnership advancing precision oncology through products and services leveraging proprietary Anchored Multiplex PCR (AMP) chemistry and informatics platform for advanced detection of gene fusions, variants, and biomarkers.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Diatech Pharmacogenetics competitors and assessment

Company assessment

Broad incumbents

  • Hologic: Major molecular diagnostics and women's health company with IVD kits sold globally. Comparable as an established IVD kit manufacturer with regulatory expertise, though with broader product portfolio and stronger US footprint.
  • Qiagen: Global molecular diagnostics and sample-preparation leader with oncology and pharmacogenetics test menus. Comparable because both sell IVD molecular diagnostic kits to clinical labs and run parallel PCR- and NGS-based workflows, though Qiagen operates at much broader scale.
  • NeoGenomics: US-based oncology-focused clinical laboratory and IVD provider offering molecular and pharmacogenomic testing. Comparable because both serve oncologists and hematologists with molecular biomarker testing for therapy selection, though NeoGenomics operates primarily as a reference lab rather than a kit vendor.
  • Bio-Techne: Diagnostics and life-science reagents company with a molecular diagnostics portfolio including ExoDx and protein biomarker assays. Comparable as a B2B IVD kit vendor serving clinical labs, though with a broader reagents portfolio and US-centric distribution.
  • Myriad Genetics: Established molecular diagnostics company with oncology and pharmacogenetics test offerings. Comparable as a long-standing IVD molecular diagnostics player serving oncologists, though with a US-centric focus and broader hereditary cancer testing franchise.
  • Cepheid (Danaher): Subsidiary of Danaher operating the GeneXpert molecular diagnostics platform. Comparable as a global molecular IVD vendor with oncology and infectious disease menus sold to hospital labs, though at much larger scale and with broader regulatory clearances.

Direct peers

  • Caris Life Sciences: Molecular diagnostics and precision oncology company offering comprehensive tumor profiling. Comparable as a precision oncology diagnostics provider offering molecular profiling for therapy selection, though Caris operates primarily as a reference lab rather than selling kits.
  • HTG Molecular Diagnostics: Developer of molecular profiling technologies and assays for oncology applications. Direct peer because both target clinical labs with multiplexed gene-expression and mutation profiling assays for solid tumor and hematology applications.
  • Agena Bioscience: Developer of the MassARRAY technology on which Diatech's Myriapod system is built. Direct peer because both commercialize MassARRAY-based CE-IVD diagnostic assays for oncology mutation testing, including the jointly launched MassARRAY Dx PLUS line.
  • Veracyte: Molecular diagnostics company focused on oncology genomic testing. Comparable as a developer of molecular IVD tests for cancer diagnosis and treatment selection, with similar target customer base of hospital pathology labs and oncologists.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Diatech Pharmacogenetics social profiles

Digital presence

Diatech Pharmacogenetics compliance and trust

Trust signal

Compliance3 records

Diatech Pharmacogenetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diatech Pharmacogenetics leadership team

Management profile

Number of profiles

Profiles5 records

Diatech Pharmacogenetics subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Diatech Pharmacogenetics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diatech Pharmacogenetics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diatech Pharmacogenetics

What does Diatech Pharmacogenetics do?

Diatech Pharmacogenetics develops, manufactures, and distributes CE-IVD marked molecular diagnostic kits and instruments for precision oncology and pharmacogenetics. Its flagship Myriapod® system enables identification of SNPs and actionable mutations (KRAS, NRAS, BRAF, EGFR, ALK) in solid tumors, blood cancers, and pharmacogenetic applications, delivering personalized therapy recommendations in less than one day. The company also manufactures the Labcycler PCR thermal cycler instrument for research and diagnostic laboratories.

Is Diatech Pharmacogenetics a public or private company?

Diatech Pharmacogenetics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Diatech Pharmacogenetics founded?

Diatech Pharmacogenetics was founded in 1999. It employs 51 to 100 people.

Where is Diatech Pharmacogenetics based?

Diatech Pharmacogenetics is headquartered in Jesi, Italy, in the Europe region.

How does Diatech Pharmacogenetics make money?

Four revenue lines are on record. Molecular Diagnostic Kits and Tests are the primary driver. The others are labcycler Instruments, RAS Biomarker Testing and OEM/Embedded Technology Licensing.

Who are Diatech Pharmacogenetics's main competitors?

Broad incumbents on record are Hologic, Qiagen, NeoGenomics, Bio-Techne, Myriad Genetics and Cepheid (Danaher). Direct peers are Caris Life Sciences, HTG Molecular Diagnostics, Agena Bioscience and Veracyte.

Does Diatech Pharmacogenetics have an API?

No public API is recorded for Diatech Pharmacogenetics.

What industry is Diatech Pharmacogenetics in?

Diatech Pharmacogenetics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWireDiatech Pharmacogenetics Expands Collaboration with Merck to Enhance Patient Access to Personalized Medicine in the Middle East and AfricaDiatech Pharmacogenetics expanded its collaboration with Merck Serono Middle East to improve access to RAS biomarker testing for colorectal cancer in the Middle East and Africa. The partnership aims to provide CE-IVD diagnostic solutions for genetic testing, with colorectal cancer projected to rise to 3.2 million new cases by 2040.Business Wire BlogDiatech Pharmacogenetics Expands Collaboration with Merck to Enhance Patient Access to Personalized Medicine in the Middle East and AfricaDiatech Pharmacogenetics announced an expansion of its collaboration with Merck Serono Middle East Ltd., affiliates of Merck KGaA, to improve patient access to RAS biomarker testing for colorectal cancer in the Middle East and Africa regions. The partnership aims to advance healthcare solutions and enable timely, accurate genetic testing for metastatic colorectal cancer patients across the MEA region. Both companies highlighted their joint commitment to addressing healthcare challenges in the region and delivering personalized treatment options to improve patient outcomes.Business Wire BlogDiatech Pharmacogenetics Announces New Collaboration to Advance Precision Testing in OncologyDiatech Pharmacogenetics announced a collaboration with Janssen Pharmaceutica to develop a molecular test for bladder cancer. The test will detect genetic alterations predictive of targeted treatments, using a rapid three-hour PCR assay. The goal is to improve access to precision oncology testing worldwide.DiatechpharmacogeneticsDiatech Pharmacogenetics Expands Collaboration with Merck to Enhance Patient Access to Personalized Medicine in the Middle East and AfricaDiatech Pharmacogenetics announced an expansion of its collaboration with Merck Serono Middle East Ltd. to enhance patient access to RAS biomarker testing for colorectal cancer in the Middle East and Africa. The partnership aims to provide precise genetic testing solutions to improve personalized treatment options for patients in the region.UnquoteAlto Partners backs DiatechAlto Partners has acquired a 40% stake in Italian pharmacogenetics specialist Diatech, with Banca Popolare di Sondrio providing debt financing for the transaction. Supported by this investment, Diatech plans to expand into international markets and widen its oncology diagnostic product range.